Browse the evidence

PPARα agonists (fibrates) lower serum triglycerides and raise HDL cholesterol by directly binding to the PPARα receptor, thereby inducing genes involved in fatty acid oxidation and peroxisome proliferation.

Fibrates are a class of drugs that work by directly activating the PPARα receptor to lower triglycerides and raise HDL. They are most effective when prescribed for specific lipid profiles, though they require higher doses than newer agents and are less selective than PPARγ agonists.

PPARs function as metabolic sensors that bind directly to a variety of natural fatty acids and oxidized fatty acid metabolites (eicosanoids), coupling fatty acid flux to the transcriptional regulation of lipid and glucose homeostasis genes.

Your body's PPAR receptors are naturally activated by the fatty acids you eat and metabolize. These receptors act as sensors, adjusting gene expression to manage lipid and glucose levels based on your dietary fat intake.

IL-6 acts as a myokine with dual roles: it enhances glucose metabolism and insulin sensitivity during exercise, but chronic overproduction (e.g., in Duchenne muscular dystrophy) contributes to muscle degeneration and inflammation.

IL-6 is a complex myokine. During exercise, it helps your muscles use glucose and fat efficiently. However, in diseases like Duchenne muscular dystrophy, too much IL-6 causes damage. Inhibiting IL-6 in these specific disease contexts can improve muscle health, highlighting that IL-6's effect depends entirely on the physiological context.

Ablation of the PPAR gamma 2 isoform prevents adipose tissue expansion, leading to lipotoxicity, severe insulin resistance, and beta-cell failure despite reduced total fat mass.

This research suggests that metabolic health is not solely determined by how much fat you carry, but by your body's ability to store that fat safely in adipose tissue. If your fat storage capacity is overwhelmed, fat spills over into organs like the liver and pancreas, causing toxicity and insulin resistance regardless of your total body weight. Focus on maintaining metabolic flexibility and healthy adipose tissue function rather than just weight loss.

PPAR gamma 2 prevents lipotoxicity in non-adipose tissues (liver, muscle, pancreas) by facilitating the deposition of fat as harmless triacylglycerols (TAGs) instead of reactive lipid species like ceramides and diacylglycerols (DAGs).

This mechanism highlights the importance of how the body handles excess fat. When the body can safely store fat as triglycerides within cells, it avoids the toxic effects of other lipid byproducts that damage cells and cause insulin resistance. This suggests that supporting healthy lipid storage pathways is crucial for metabolic health.

PPAR gamma 2 is required for the adaptive beta-cell hyperplasia and hypertrophy that normally compensates for insulin resistance.

Beta cells can adapt to insulin resistance by increasing in number and size, but this adaptation requires specific molecular signals like PPARg2. Without these signals, beta cells fail to adapt, leading to diabetes even if insulin resistance itself is not the primary driver.

Leptin plays a critical role in linking nutritional status to immune function, specifically by stimulating T-cell proliferation and proinflammatory cytokine production.

Leptin, a hormone produced by fat cells, helps regulate your immune system. In obesity, this system can become dysregulated. Understanding this link highlights why metabolic health is crucial for immune resilience, though current research does not support leptin supplementation as a standard immune booster for obese individuals.

Acquired obesity, independent of genetic factors, causes deleterious alterations in serum lipid metabolism characterized by increased lysophosphatidylcholines (LPCs) and decreased ether phospholipids, which facilitate inflammation, atherogenesis, and insulin resistance.

Your lipid profile is not fixed by your DNA. Gaining weight triggers specific chemical changes in your blood (increased LPCs, decreased protective ether phospholipids) that promote inflammation and insulin resistance. Losing weight or preventing weight gain can mitigate these specific risks, regardless of your genetic background.

Endurance training under simulated hypoxic conditions (3,850m) induces specific molecular adaptations in human skeletal muscle, including increased HIF-1a, myoglobin, and VEGF mRNA, which do not translate to greater global functional improvements (VO2max or power output) compared to normoxic training.

If your goal is to maximize VO2max or power output, training at simulated altitude (3,850m) offers no advantage over training at sea level. You will see similar functional gains. However, if you are interested in specific molecular adaptations like increased oxygen-sensing capacity (HIF-1) or oxygen transport proteins (myoglobin/VEGF), hypoxic training may be relevant, though these changes do not currently translate to better performance metrics in untrained individuals.

Loss of ovarian function (menopause) causes obesity and metabolic dysfunction primarily through reduced energy expenditure and increased adipose tissue inflammation, independent of increased food intake.

Postmenopausal weight gain is not just about eating more; your body burns fewer calories at rest. Focus on strategies that support metabolic rate and manage inflammation, rather than assuming the issue is solely caloric intake.

Ovariectomy induces visceral adipose tissue inflammation characterized by T-cell infiltration and M1 macrophage polarization, which contributes to insulin resistance.

Visceral fat becomes inflamed after menopause due to immune cell infiltration. This inflammation drives insulin resistance, suggesting anti-inflammatory strategies may be beneficial.

Hepatic insulin resistance promotes de novo lipogenesis (DNL) via upregulation of SREBP1c and ChREBP, contributing to liver fat accumulation.

Limiting carbohydrate intake, especially simple sugars, can reduce the substrate and signaling for DNL, thereby lowering liver fat production.

Low birth weight (indicative of intra-uterine growth retardation) is associated with an increased risk of coronary heart disease, stroke, and diabetes in adulthood.

Pregnant women should be monitored for fetal growth restriction, as low birth weight is a marker for increased adult cardiovascular and metabolic risk.

Women exhibit lower biological aging and greater longevity than men, evidenced by molecular biomarkers, higher mitochondrial function, and longer telomeres, despite experiencing higher frailty and worse health outcomes at the end of life.

Biological aging is not identical between sexes. Women generally show molecular signs of slower aging (better mitochondrial function, longer telomeres) and live longer, but often suffer more from frailty and chronic disease in old age. Men may maintain physical function longer but face higher risks of early mortality and specific diseases. Personalized health strategies should account for these inherent biological differences rather than applying a one-size-fits-all approach to aging.

Estrogen and other sex hormones play a protective role in mitochondrial function and aging, with women showing higher mitochondrial gene expression and activity compared to men.

Hormones, particularly estrogen, significantly impact how your cells produce energy and age. Women naturally have more active mitochondria, which contributes to their longer lifespan. As estrogen levels drop after menopause, this protective effect diminishes, potentially accelerating certain aspects of aging. Maintaining metabolic health becomes crucial during this transition.

Telomere length is sexually dimorphic, with women having longer telomeres than men from birth, which may contribute to their longer lifespan, although the causal relationship is complex and influenced by genetics and stress.

Women naturally have longer telomeres, a marker of cellular aging, which may help explain their longer lifespan. However, telomeres shorten due to stress, genetics, and lifestyle factors. While you cannot change your sex, managing stress and maintaining a healthy lifestyle can help preserve telomere length.

Higher leg fat mass is independently associated with lower fasting and postload glucose levels, suggesting a protective effect against disturbed glucose metabolism.

Do not strive to lose fat from your legs if you have high trunk fat. Leg fat may help protect your blood sugar levels. Focus weight loss efforts on the abdominal area.

Intracerebroventricular infusion of leptin attenuates the rewarding effect of lateral hypothalamic stimulation in brain regions sensitive to chronic food restriction, while enhancing it in insensitive regions.

Leptin, a hormone from fat cells, doesn't just suppress appetite; it actively changes how rewarding certain brain activities feel. In areas linked to feeding, leptin makes stimulation less rewarding, potentially reducing the drive to eat. However, in other brain areas, it makes stimulation more rewarding, possibly encouraging other behaviors. This suggests leptin helps shift your focus away from food when energy stores are sufficient.

Physiological adaptations to weight loss, including hormonal shifts and reduced energy expenditure, actively favor weight regain, making long-term maintenance difficult without medical intervention.

If you have lost weight, expect your body to fight to regain it through increased hunger and slower metabolism. This is a biological adaptation, not a failure of will. To maintain loss, you likely need to address this physiology directly, potentially through medical interventions or surgery, as behavioral strategies alone are often insufficient against these strong biological drives.

Gastric bypass surgery alters gut hormone levels (low ghrelin, high GLP-1/PYY) in a way that attenuates appetite, contributing to its efficacy as a treatment for obesity.

Gastric bypass surgery works partly by changing gut hormones to reduce appetite (low ghrelin, high GLP-1/PYY). This hormonal shift helps explain why surgery is often more effective than diet/exercise alone for long-term weight loss.

Adiponectin levels decrease in obesity and contribute to cardiovascular risk by failing to provide anti-inflammatory and anti-atherogenic protection to the vessel wall.

Maintaining healthy adiponectin levels through weight management supports blood vessel health. Low levels, common in obesity, remove a natural protective barrier against inflammation and atherosclerosis.

Elevated plasma free fatty acids (FFAs) induce endothelial dysfunction primarily by downregulating the AMPK/PI3K/Akt/eNOS signaling pathway, thereby reducing nitric oxide (NO) production and causing vasoconstriction.

If you have metabolic issues like obesity or type 2 diabetes, your body may have high levels of free fatty acids in your blood. This specifically damages the lining of your blood vessels by blocking the production of nitric oxide, which keeps arteries flexible. Managing metabolic health through diet and exercise can lower these fatty acids and protect your vascular function.

Elevated free fatty acids promote endothelial dysfunction by activating inflammatory pathways (NF-κB) and oxidative stress (NADPH oxidase), leading to reduced nitric oxide availability and increased vasoconstrictors like endothelin-1.

High levels of fatty acids in the blood trigger inflammation and oxidative stress in blood vessel walls. This damage reduces the body's ability to produce nitric oxide (a vessel relaxer) and increases substances that tighten vessels. Reducing metabolic stress helps lower this inflammatory burden.

Inflammaging, characterized by chronic low-grade elevation of proinflammatory cytokines (IL-6, TNF, IL-1), drives age-related functional decline, sarcopenia, and frailty through tissue damage and immune remodelling.

Chronic, low-grade inflammation is a primary driver of muscle loss and frailty in older adults. Managing body composition (reducing visceral fat) and stress (to modulate cortisol/DHEAS ratios) are key strategies to mitigate this inflammatory burden and preserve functional ability.